Data as of Mar 14
| -0.15 / -3.44%|
The 2 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 9.50, with a high estimate of 11.00 and a low estimate of 8.00. The median estimate represents a +125.65% increase from the last price of 4.21.
The current consensus among 3 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.